These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 9591210)

  • 1. The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of type I collagen, new markers of bone resorption.
    Taga M; Uemura T; Minaguchi H
    J Endocrinol Invest; 1998 Mar; 21(3):154-9. PubMed ID: 9591210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in urinary excretions of C-telopeptide and cross-linked N-telopeptide of type I collagen during pregnancy and puerperium.
    Yamaga A; Taga M; Minaguchi H
    Endocr J; 1997 Oct; 44(5):733-8. PubMed ID: 9466331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in urinary excretion of type-I collagen cross-linked C-telopeptide and N-telopeptide in perimenopausal women.
    Taga M; Shirashu K; Minaguchi H
    Horm Res; 1998; 49(2):86-90. PubMed ID: 9485177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
    Garnero P; Hausherr E; Chapuy MC; Marcelli C; Grandjean H; Muller C; Cormier C; Bréart G; Meunier PJ; Delmas PD
    J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New biochemical markers of bone resorption in the study of postmenopausal osteoporosis.
    de la Piedra C; Traba ML; Dominguez Cabrera C; Sosa Henríquez M
    Clin Chim Acta; 1997 Sep; 265(2):225-34. PubMed ID: 9385464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
    Chaki O; Yoshikata I; Kikuchi R; Nakayama M; Uchiyama Y; Hirahara F; Gorai I
    J Bone Miner Res; 2000 Aug; 15(8):1537-44. PubMed ID: 10934652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific changes of urinary excretion of cross-linked N-telopeptides of type I collagen in pre- and postmenopausal women: correlation with other markers of bone turnover.
    Gorai I; Taguchi Y; Chaki O; Nakayama M; Minaguchi H
    Calcif Tissue Int; 1997 Apr; 60(4):317-22. PubMed ID: 9075625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density.
    Chesnut CH; Bell NH; Clark GS; Drinkwater BL; English SC; Johnson CC; Notelovitz M; Rosen C; Cain DF; Flessland KA; Mallinak NJ
    Am J Med; 1997 Jan; 102(1):29-37. PubMed ID: 9209198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism.
    Minisola S; Pacitti MT; Rosso R; Pellegrino C; Ombricolo E; Pisani D; Romagnoli E; Damiani C; Aliberti G; Scarda A; Mazzuoli SF
    J Endocrinol Invest; 1997 Oct; 20(9):559-65. PubMed ID: 9413811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I.
    Reginster JY; Henrotin Y; Christiansen C; Gamwell-Henriksen E; Bruyere ; Collette J; Christgau S
    Calcif Tissue Int; 2001 Sep; 69(3):130-7. PubMed ID: 11683527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover.
    Amama EA; Taga M; Minaguchi H
    J Clin Endocrinol Metab; 1998 Feb; 83(2):333-8. PubMed ID: 9467536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ; Chesnut CH; Mallinak NJ
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
    Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
    J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
    Eastell R; Barton I; Hannon RA; Chines A; Garnero P; Delmas PD
    J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density.
    Schneider DL; Barrett-Connor EL
    Arch Intern Med; 1997 Jun; 157(11):1241-5. PubMed ID: 9183236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.
    Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Pons F; Martínez de Osaba MJ; Echevarría M; Ballesta AM; Muñoz-Gómez J
    Bone; 1999 Sep; 25(3):349-53. PubMed ID: 10495139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover.
    Raisz L; Smith JA; Trahiotis M; Fall P; Shoukri K; Digennaro J; Sacco-Gibson N
    Osteoporos Int; 2000; 11(7):615-20. PubMed ID: 11069196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
    Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y
    J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.